tiprankstipranks
Satellos Bioscience (TSE:MSCL)
TSX:MSCL

Satellos Bioscience (MSCL) Price & Analysis

Compare
24 Followers

MSCL Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
Clinical Trials ProgressSatellos is steadily advancing its ongoing Phase 1 study evaluating SAT-3247’s safety and pharmacokinetics in healthy volunteers.
Safety ProfileNo drug-related adverse events have been reported to date in the Phase 1 study of SAT-3247.
Bears Say
Risks And ChallengesRisks identified include clinical, regulatory, commercial, competition, and dilution.
---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

23.54%76.46%
23.54% Insiders
― Other Institutional Investors
76.46% Public Companies and
Individual Investors

MSCL FAQ

What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$0.38 and its highest was C$1.32 in the past 12 months.
    What is Satellos Bioscience’s market cap?
    Satellos Bioscience’s market cap is $136.50M.
      When is Satellos Bioscience’s upcoming earnings report date?
      Satellos Bioscience’s upcoming earnings report date is Mar 27, 2025 which is in 13 days.
        How were Satellos Bioscience’s earnings last quarter?
        Satellos Bioscience released its earnings results on Nov 13, 2024. The company reported -C$0.08 earnings per share for the quarter, missing the consensus estimate of -C$0.05 by -C$0.03.
          Is Satellos Bioscience overvalued?
          According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Satellos Bioscience pay dividends?
            Satellos Bioscience does not currently pay dividends.
            What is Satellos Bioscience’s EPS estimate?
            Satellos Bioscience’s EPS estimate is -0.04.
              How many shares outstanding does Satellos Bioscience have?
              Satellos Bioscience has 153,375,400 shares outstanding.
                What happened to Satellos Bioscience’s price movement after its last earnings report?
                Satellos Bioscience reported an EPS of -C$0.08 in its last earnings report, missing expectations of -C$0.05. Following the earnings report the stock price went up 1.19%.
                  Which hedge fund is a major shareholder of Satellos Bioscience?
                  Currently, no hedge funds are holding shares in TSE:MSCL
                  ---

                  Company Description

                  Satellos Bioscience

                  Satellos Bioscience (MSCL) is a biotechnology company focused on the development of novel therapeutic solutions aimed at muscle regeneration and repair. The company operates within the life sciences sector and leverages advanced scientific research to address degenerative muscle diseases. Satellos' core product offerings include proprietary drug candidates designed to stimulate and enhance muscle regeneration processes, potentially transforming the treatment landscape for conditions such as Duchenne Muscular Dystrophy.
                  ---

                  MSCL Stock 12 Month Forecast

                  Average Price Target

                  C$1.25
                  ▲(35.90% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"C$2","-1":"-C$1","-0.25":"-C$0.25","0.5":"C$0.5","1.25":"C$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.2500000035119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$1.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.2503197692,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$1.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.2500000035119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$1.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Apr<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7515384618086076,0.7930769236172154,0.834615385425823,0.8761538472344308,0.9176923090430384,0.9592307708516461,1.0007692326602537,1.0423076944688616,1.0838461562774693,1.125384618086077,1.1669230798946848,1.2084615417032922,{"y":1.2500000035119,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7515630591692307,0.7931261183384615,0.8346891775076923,0.8762522366769231,0.9178152958461538,0.9593783550153847,1.0009414141846156,1.0425044733538462,1.0840675325230769,1.1256305916923077,1.1671936508615386,1.2087567100307695,{"y":1.2503197692,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.7515384618086076,0.7930769236172154,0.834615385425823,0.8761538472344308,0.9176923090430384,0.9592307708516461,1.0007692326602537,1.0423076944688616,1.0838461562774693,1.125384618086077,1.1669230798946848,1.2084615417032922,{"y":1.2500000035119,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.345,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.475,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.45,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.53,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.69,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.5,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.5,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Theratechnologies
                  Oncolytics Biotech

                  Best Analysts Covering MSCL

                  1 Year
                  Arthur He CFAH.C. Wainwright
                  1 Year Success Rate
                  6/6 ratings generated profit
                  100%
                  1 Year Average Return
                  +53.12%
                  reiterated a buy rating 4 months ago
                  Copying Arthur He CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.12% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis